Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407915 | 1.00 | KMT2A (0.33) | KMT2AMEN1PKMLMNAMAPT | |
| SCHEMBL2407501 | 0.89 | ALDH1A1 (0.38) | LMNAMAPTTSHRHTTSMN1; SMN2 | |
| SCHEMBL2407505 | 0.89 | ALDH1A1 (0.38) | LMNAMAPTTSHRHTTSMN1; SMN2 | |
| SCHEMBL2406887 | 0.89 | SLC6A4 (0.46) | MAPTSLC6A4ALDH1A1 | |
| SCHEMBL2406883 | 0.89 | SLC6A4 (0.46) | MAPTSLC6A4ALDH1A1 | |
| SCHEMBL925432 | 0.84 | SLC6A4 (0.33) | SLC6A4 | |
| SCHEMBL925434 | 0.84 | SLC6A4 (0.33) | SLC6A4 | |
| SCHEMBL3719565 | 0.82 | SLC6A4 (0.32) | SLC6A4 | |
| SCHEMBL2404171 | 0.82 | — | — | |
| SCHEMBL2404168 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2212317-A1 | 4,4-DISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053452-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | REN, AGTR2, AVPR2 | KMT2A 3109/4885MEN1 3009/4885PKM 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.